30 Ağustos 2021 Dergi makalesi Açık Erişim

Ebru; Salih; Tuğba; Ömer Faruk; Öznur Özge; Tuğçe; Mesut; Muhsin

JSON-LD (schema.org)

{
  "@context": "https://schema.org/", 
  "@id": 227979, 
  "@type": "ScholarlyArticle", 
  "creator": [
    {
      "@id": "https://orcid.org/0000-0002-0395-9845", 
      "@type": "Person", 
      "affiliation": "\u00d6ZKAN OKTAY", 
      "name": "Ebru"
    }, 
    {
      "@id": "https://orcid.org/0000-0003-3838-5228", 
      "@type": "Person", 
      "affiliation": "TUNCAY", 
      "name": "Salih"
    }, 
    {
      "@id": "https://orcid.org/0000-0002-5885-0193", 
      "@type": "Person", 
      "affiliation": "KAMAN", 
      "name": "Tu\u011fba"
    }, 
    {
      "@id": "https://orcid.org/0000-0001-7803-3249", 
      "@type": "Person", 
      "affiliation": "KARASAKAL", 
      "name": "\u00d6mer Faruk"
    }, 
    {
      "@id": "https://orcid.org/0000-0001-8992-0556", 
      "@type": "Person", 
      "affiliation": "\u00d6ZCAN", 
      "name": "\u00d6znur \u00d6zge"
    }, 
    {
      "@id": "https://orcid.org/0000-0002-4663-897X", 
      "@type": "Person", 
      "affiliation": "SOYLAMI\u015e", 
      "name": "Tu\u011f\u00e7e"
    }, 
    {
      "@id": "https://orcid.org/0000-0002-8971-678X", 
      "@type": "Person", 
      "affiliation": "KARAHAN", 
      "name": "Mesut"
    }, 
    {
      "@id": "https://orcid.org/0000-0002-6651-718X", 
      "@type": "Person", 
      "affiliation": "KONUK", 
      "name": "Muhsin"
    }
  ], 
  "datePublished": "2021-08-30", 
  "description": "<p>Various recently reported mutant variants, candidate and urgently approved current vaccines against severe acute respiratory&nbsp;syndrome coronavirus 2 (SARS-CoV-2), many current situations with severe neurological damage and symptoms as well as respiratory&nbsp;tract disorders have begun to be reported. In particular, drug, vaccine, and neutralizing monoclonal antibodies (mAbs) have been&nbsp;developed and are currently being evaluated in clinical trials. Here, we review lessons learned from the use of novel mutant variants&nbsp;of the COVID-19 virus, immunization, new drug solutions, and antibody therapies for infections. Next, we focus on the B 1.1.7, B&nbsp;1.351, P.1, and B.1.617 lineages or variants of concern that have been reported worldwide, the new manifestations of neurological&nbsp;manifestations, the current therapeutic drug targets for its treatment, vaccine candidates and their efficacy, implantation of convalescent&nbsp;plasma, and neutralization of mAbs. We review specific clinical questions, including many emerging neurological effects and respiratory&nbsp;tract injuries, as well as new potential biomarkers, new studies in addition to known therapeutics, and chronic diseases of vaccines&nbsp;that have received immediate approval. To answer these questions, further understanding of the burden kinetics of COVID-19 and its&nbsp;correlation with neurological clinical outcomes, endogenous antibody responses to vaccines, pharmacokinetics of neutralizing mAbs,&nbsp;and action against emerging viral mutant variants is needed.</p>", 
  "headline": "An update comprehensive review on the status of COVID-19: vaccines, drugs, variants and neurological symptoms", 
  "identifier": 227979, 
  "image": "https://aperta.ulakbim.gov.tr/static/img/logo/aperta_logo_with_icon.svg", 
  "keywords": [
    "COVID-19", 
    "variants", 
    "neurological symptoms", 
    "drugs", 
    "vaccines", 
    "neutralizing antibodies", 
    "SARS-CoV-2"
  ], 
  "license": "http://www.opendefinition.org/licenses/cc-by-sa", 
  "name": "An update comprehensive review on the status of COVID-19: vaccines, drugs, variants and neurological symptoms", 
  "url": "https://aperta.ulakbim.gov.tr/record/227979"
}